Cheng JT, Yao YH, Gao YE, et al. - In 89 patients suffering from EGFR (epidermal growth factor receptor) T790M-positive advanced NSCLC (non-small cell lung cancer), researchers assessed if improvement in survival outcomes could result from rebiopsy analysis following osimertinib progression. In this single-center retrospective cohort study, participants were treated with second- or further-line osimertinib between January 2017 and July 2019. Findings showed that, following osimertinib progression, combined histological and molecular analyses of rebiopsy specimens could afford more opportunities for individualized treatments to improve the post-progression survival of these patients. Based on clinical evidence gained through this study, next-generation sequencing-based analysis of rebiopsy specimens deserves to be included as standard-of-care after osimertinib progression. Participants who had histological and molecular analyses of rebiopsy samples done at osimertinib progression, especially those who had actionable markers and were able receive highly matched therapy, had significantly prolonged post-progression progression-free survival and post-progression overall survival vs those who received low-level matched therapy, unmatched therapy, and those with no rebiopsy data.